A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

ClinicalTrials.gov ID: NCT05828589

Public ClinicalTrials.gov record NCT05828589. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Optimization."

Study identification

NCT ID: NCT05828589
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 51 participants

Conditions and interventions

Conditions

Interventions

BGB-21447 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 20, 2023 (Actual)
Primary completion: Jun 8, 2026 (Actual)
Completion: Jun 8, 2026 (Actual)
Last update posted: Jul 14, 2026

2023 – 2026

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Sibley Memorial Hospital Johns Hopkins Medicine	Washington D.C.	District of Columbia	20016	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242-1009	—
Mission Cancer and Blood	Waukee	Iowa	50263	—
Sidney Kimmel Comprehensive Cancer At Johns Hopkins	Baltimore	Maryland	21287	—
Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island	Mineola	New York	11501	—
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health	New York	New York	10016-2708	—
Avera Cancer Institute	Sioux Falls	South Dakota	57105-2108	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05828589, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2026 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05828589 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →